Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Pulmonary Hypertension, February 2019 Free Subscription Abstracts Retrieve all available abstracts of the following 146 articles: HTML format

Single Articles

1. AVDEEV SN, Gaynitdinova VV, Tsareva NA, Merzhoeva ZM, et al
   [Natriuretic peptides as markers of development and prognosis of pulmonary hypertension severity in patients with chronic obstructive disease.]
   Klin Lab Diagn. 2018;63:333-337.
   Abstract    
   
   Abstract available
   
   

2. MARTYNYUK TV, Nakonechnikov SN, Chazova IY
   New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
   Ter Arkh. 2018;90:72-80.
   Abstract    
   
   Abstract available
   
   

3. VALIEVA ZS, Taran IN, Martynyuk TV, Chazova IY, et al
   Modern view on the place of riociguat in the treatment of pulmonary hypertension.
   Ter Arkh. 2018;90:55-59.
   Abstract    
   
   Abstract available
   
   

4. CHAZOVA IE, Martynyuk TV, Valieva ZS, Nakonechnikov SN, et al
   The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation.
   Ter Arkh. 2018;90:101-109.
   Abstract    
   
   Abstract available
   
   

5. BARNES H, Brown Z, Burns A, Williams T, et al
   Phosphodiesterase 5 inhibitors for pulmonary hypertension.
   Cochrane Database Syst Rev. 2019;1:CD012621.
   Abstract    
   
   Abstract available
   
   

6. VULLAGANTI S, Tibrewala A, Rich J, Pham DT, et al
   EXPRESS: The use of a durable right ventricular assist device for isolated right ventricular failure due to combined pre- and postcapillary pulmonary hypertension.
   Pulm Circ. 2019 Jan 30:2045894019831222. doi: 10.1177/2045894019831222.
   Abstract    
   
   
   
   

7. AKAGI S, Ejiri K, Kasahara S, Nakamura K, et al
   EXPRESS: Improvement of Lung Function and Pulmonary Hypertension After Pulmonary Aneurysm Repair: Case Series.
   Pulm Circ. 2019 Jan 30:2045894019831217. doi: 10.1177/2045894019831217.
   Abstract    
   
   
   
   

8. MEHRA P, Mehta V, Sukhija R, Sinha AK, et al
   Pulmonary hypertension in left heart disease.
   Arch Med Sci. 2019;15:262-273.
   Abstract    
   
   
   
   

9. KALANTARI KR, Malek H, Amin A, Moosavi J, et al
   Chronic thromboembolic pulmonary hypertension versus fibrosing mediastinitis.
   Anatol J Cardiol. 2019;21:E4-E5.
   Abstract    
   
   
   
   

10. NILSSON KF, Gustafsson LE
    Treatment with new organic nitrites in pulmonary hypertension of acute experimental pulmonary embolism.
    Pharmacol Res Perspect. 2019;7:e00462.
    Abstract    
    
    Abstract available
    
    

11. SMITH ZR, Rangarajan K, Barrow J, Carter D, et al
    Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method.
    Am J Health Syst Pharm. 2019;76:153-165.
    Abstract    
    
    Abstract available
    
    

12. HABASH S, Laser KT, Moosmann J, Reif R, et al
    Normal values of the pulmonary artery acceleration time (PAAT) and the right ventricular ejection time (RVET) in children and adolescents and the impact of the PAAT/RVET-index in the assessment of pulmonary hypertension.
    Int J Cardiovasc Imaging. 2019 Jan 28. pii: 10.1007/s10554-019-01540.
    Abstract    
    
    Abstract available
    
    

13. MULCHRONE A, Kellihan HB, Forouzan O, Hacker TA, et al
    A Large Animal Model of Right Ventricular Failure due to Chronic Thromboembolic Pulmonary Hypertension: A Focus on Function.
    Front Cardiovasc Med. 2019;5:189.
    Abstract    
    
    Abstract available
    
    

14. ARVANITAKI A, Mouratoglou SA, Evangeliou A, Grosomanidis V, et al
    Quality of Life is Related to Haemodynamics in Precapillary Pulmonary Hypertension.
    Heart Lung Circ. 2019 Jan 15. pii: S1443-9506(19)30025.
    Abstract    
    
    Abstract available
    
    

15. RACHDI I, Tougorti M, Daoud F, Aydi Z, et al
    Pulmonary hypertension on systemic sclerosis-lupus erythematosus overlap syndrome.
    Ann Cardiol Angeiol (Paris). 2019 Jan 23. pii: S0003-3928(18)30201.
    Abstract    
    
    Abstract available
    
    

16. YOSHIHISA A, Yokokawa T, Misaka T, Oikawa M, et al
    Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.
    ESC Heart Fail. 2019 Jan 25. doi: 10.1002/ehf2.12404.
    Abstract    
    
    Abstract available
    
    

17. GHAEMIAN A, Nabati M, Dabirian M, Shokri M, et al
    Isolated partial right lower lobe pulmonary venous drainage into the right atrium as a cause of pulmonary hypertension in a middle-aged woman.
    J Clin Ultrasound. 2019 Jan 25. doi: 10.1002/jcu.22691.
    Abstract    
    
    Abstract available
    
    

18. ZHAO J, Yang M, Wu X, Yang Z, et al
    Effects of paclitaxel intervention on pulmonary vascular remodeling in rats with pulmonary hypertension.
    Exp Ther Med. 2019;17:1163-1170.
    Abstract    
    
    Abstract available
    
    

19. AGGARWAL M, Schuettpelz L, Kolodziej J, Grady RM, et al
    Rapid development of pulmonary hypertension during treatment of paediatric cancer.
    Cardiol Young. 2019 Jan 25:1-4. doi: 10.1017/S1047951118002196.
    Abstract    
    
    Abstract available
    
    

20. NTILOUDI D, Zanos S, Gatzoulis MA, Karvounis H, et al
    How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension.
    Expert Rev Cardiovasc Ther. 2019;17:11-18.
    Abstract    
    
    Abstract available
    
    

21. ASTADICKO I, Dresse MF, Seghaye MC
    [Cardiac complications of sickle cell disease in children].
    Rev Med Liege. 2018;73:550-556.
    Abstract    
    
    Abstract available
    
    

22. ZHU G, Zhang W, Liu Y, Wang S, et al
    miR371b5p inhibits endothelial cell apoptosis in monocrotalineinduced pulmonary arterial hypertension via PTEN/PI3K/Akt signaling pathways.
    Mol Med Rep. 2018;18:5489-5501.
    Abstract    
    
    Abstract available
    
    

23. CHOI S, Park SI, Lee GD, Kim HR, et al
    The First Living-Donor Lobar Lung Transplantation in Korea: a Case Report.
    J Korean Med Sci. 2018;33:e282.
    Abstract    
    
    Abstract available
    
    

24. VORSELAARS VMM, Hosman AE, Westermann CJJ, Snijder RJ, et al
    Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.
    Int J Mol Sci. 2018;19.
    Abstract    
    
    Abstract available
    
    

25. MANAKENG K, Prasertphol P, Phongpao K, Chuncharunee S, et al
    Elevated levels of platelet- and red cell-derived extracellular vesicles in transfusion-dependent beta-thalassemia/HbE patients with pulmonary arterial hypertension.
    Ann Hematol. 2019;98:281-288.
    Abstract    
    
    Abstract available
    
    

26. JOYCE KE, Lucas SJE, Imray CHE, Balanos GM, et al
    Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema.
    Expert Opin Pharmacother. 2018;19:1891-1902.
    Abstract    
    
    Abstract available
    
    

27. RIZZI M, Radovanovic D, Santus P, Airoldi A, et al
    Usefulness of six-minute walk test in systemic sclerosis.
    Clin Exp Rheumatol. 2018;36 Suppl 113:161-167.
    Abstract    
    
    Abstract available
    
    

28. BACIK P, Poliacikova P, Kaliska G
    Who needs a permanent pacemaker after transcatheter aortic valve implantation?
    Bratisl Lek Listy. 2018;119:560-565.
    Abstract    
    
    Abstract available
    
    

29. YUE Y, Zhang Z, Zhang L, Chen S, et al
    miR-143 and miR-145 promote hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells through regulating ABCA1 expression.
    Cardiovasc Pathol. 2018;37:15-25.
    Abstract    
    
    Abstract available
    
    

30. VANDECASTEELE E, Melsens K, De Keyser F, De Pauw M, et al
    A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
    Clin Exp Rheumatol. 2018;36 Suppl 113:95-101.
    Abstract    
    
    Abstract available
    
    

31. CICCO S, Leone P, Racanelli V, Vacca A, et al
    Mucine-1 Is Related to Cell-Mediated Immunoexpression and Blood Pressure in Pulmonary Artery in Pulmonary Arterial Hypertension (PAH): Preliminary Results.
    Adv Exp Med Biol. 2018;1072:275-280.
    Abstract    
    
    Abstract available
    
    

32. TELLO K, Axmann J, Ghofrani HA, Naeije R, et al
    Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension.
    Int J Cardiol. 2018;266:229-235.
    Abstract    
    
    Abstract available
    
    

33. LEIFER FG, Konicek DM, Chen KJ, Plaunt AJ, et al
    Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation.
    Drug Res (Stuttg). 2018;68:605-614.
    Abstract    
    
    Abstract available
    
    

34. LUPPINO ASSAD AP, Gavilanes Oleas F, Alves JL Jr, Dos Santos Fernandes CJC, et al
    Survival of connective tissue disease associated pulmonary arterial hypertension.
    Clin Exp Rheumatol. 2018;36 Suppl 113:186.
    Abstract    
    
    
    
    

35. CHEN F, Wang H, Lai J, Cai S, et al
    3-Bromopyruvate reverses hypoxia-induced pulmonary arterial hypertension through inhibiting glycolysis: In vitro and in vivo studies.
    Int J Cardiol. 2018;266:236-241.
    Abstract    
    
    Abstract available
    
    

36. RUAN HY, Zhang YG, Liu R
    [Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension].
    Zhonghua Yi Xue Za Zhi. 2018;98:678-681.
    Abstract    
    
    Abstract available
    
    

37. VIONNET J, Yerly P, Aubert JD, Pascual M, et al
    Management of severe portopulmonary hypertension with dual oral therapy prior to liver transplantation.
    Transplantation. 2018 Feb 26. doi: 10.1097/TP.0000000000002142.
    Abstract    
    
    
    
    

38. WALIGORA M, Tyrka A, Miszalski-Jamka T, Urbanczyk-Zawadzka M, et al
    Right atrium enlargement predicts clinically significant supraventricular arrhythmia in patients with pulmonary arterial hypertension.
    Heart Lung. 2018;47:237-242.
    Abstract    
    
    Abstract available
    
    

39. MICKAEL CS, Graham BB
    The Role of Type 2 Inflammation in Schistosoma-Induced Pulmonary Hypertension.
    Front Immunol. 2019;10:27.
    Abstract    
    
    Abstract available
    
    

40. DIMOPOULOS K, Ernst S, McCabe C, Kempny A, et al
    Pulmonary Artery Denervation: A New, Long-Awaited Interventional Treatment for Combined Pre- and Post-Capillary Pulmonary Hypertension?
    JACC Cardiovasc Interv. 2019;12:285-288.
    Abstract    
    
    
    
    

41. ZHANG H, Zhang J, Chen M, Xie DJ, et al
    Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure: The PADN-5 Study.
    JACC Cardiovasc Interv. 2019;12:274-284.
    Abstract    
    
    Abstract available
    
    

42. FORIS V, Brcic L, Douschan P, Kovacs G, et al
    EXPRESS: Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT.
    Pulm Circ. 2019 Feb 7:2045894019832214. doi: 10.1177/2045894019832214.
    Abstract    
    
    
    
    

43. PRICE LC, Seckl MJ, Dorfmuller P, Wort SJ, et al
    Tumoral pulmonary hypertension.
    Eur Respir Rev. 2019;28.
    Abstract    
    
    Abstract available
    
    

44. LIGON RA, Petit CJ
    Working backward: Retrograde balloon angioplasty of atretic arteries in chronic thromboembolic pulmonary hypertension.
    Catheter Cardiovasc Interv. 2019 Feb 5. doi: 10.1002/ccd.28115.
    Abstract    
    
    Abstract available
    
    

45. APATEAN D, Rakic B, Brunel-Guitton C, Hendson G, et al
    Congenital lactic acidosis, cerebral cysts and pulmonary hypertension in an infant with FOXRED1 related complex I deficiency.
    Mol Genet Metab Rep. 2019;18:32-38.
    Abstract    
    
    Abstract available
    
    

46. ALBANI S, Biondi F, Stolfo D, Lo Giudice F, et al
    Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature.
    J Cardiovasc Med (Hagerstown). 2019 Jan 31. doi: 10.2459/JCM.0000000000000774.
    Abstract    
    
    Abstract available
    
    

47. SOHN DW, Park JB, Lee SP, Kim HK, et al
    EXPRESS: Clinical Implication of Right-Sided Augmentation Pressure in Patients with Pulmonary Hypertension.
    Pulm Circ. 2019 Feb 5:2045894019833352. doi: 10.1177/2045894019833352.
    Abstract    
    
    
    
    

48. HINRICHS L, Horacek M, Neudorf U, Schlosser T, et al
    Diagnostic Work-Up of Pulmonary Hypertension - Think About Shunt Flow! A Case Report.
    Am J Case Rep. 2019;20:154-158.
    Abstract    
    
    Abstract available
    
    

49. CAI G, Liu J, Wang M, Su L, et al
    Mutual promotion of FGF21 and PPARgamma attenuates hypoxia-induced pulmonary hypertension.
    Exp Biol Med (Maywood). 2019 Feb 2:1535370219828692.
    Abstract    
    
    Abstract available
    
    

50. FAN F, Tian H, Geng J, Deng J, et al
    Mechanism of Beraprost Effects on Pulmonary Hypertension: Contribution of Cross-Binding to PGE2 Receptor 4 and Modulation of O2 Sensitive Voltage-Gated K(+) Channels.
    Front Pharmacol. 2019;9:1518.
    Abstract    
    
    Abstract available
    
    

51. BARNIKEL M, Kneidinger N, Klenner F, Waelde A, et al
    EXPRESS: Real-life data on Selexipag for the treatment of Pulmonary Hypertension.
    Pulm Circ. 2019 Feb 4:2045894019832199. doi: 10.1177/2045894019832199.
    Abstract    
    
    
    
    

52. TRUONG L, Zheng YM, Wang YX
    Mitochondrial Rieske iron-sulfur protein in pulmonary artery smooth muscle: A key primary signaling molecule in pulmonary hypertension.
    Arch Biochem Biophys. 2019 Jan 30. pii: S0003-9861(18)30669.
    Abstract    
    
    Abstract available
    
    

53. MAKKER K, Afolayan AJ, Teng RJ, Konduri GG, et al
    Altered hypoxia-inducible factor-1alpha (HIF-1alpha) signaling contributes to impaired angiogenesis in fetal lambs with persistent pulmonary hypertension of the newborn (PPHN).
    Physiol Rep. 2019;7:e13986.
    Abstract    
    
    Abstract available
    
    

54. HARDER EM, Fares WH
    Hospitalizations with hereditary hemorrhagic telangiectasia and pulmonary hypertension in the United States from 2000 to 2014.
    Respir Med. 2019;147:26-30.
    Abstract    
    
    Abstract available
    
    

55. CHERNYAVSKIY AM, Edemskiy AG, Novikova NV, Romanov AB, et al
    Radiofrequency Pulmonary Artery Ablation for Treatment of Residual Pulmonary Hypertension After Pulmonary Endarterectomy.
    Kardiologiia. 2018;58:15-21.
    Abstract    
    
    Abstract available
    
    

56. BHYRAVAVAJHALA S, Yerram S, Galla R, Kotapati VSK, et al
    Reliability of Doppler echocardiography in the assessment of high pulmonary vascular resistance in patients with severe pulmonary arterial hypertension.
    Indian Heart J. 2018;70 Suppl 3:S241-S244.
    Abstract    
    
    Abstract available
    
    

57. ZHANG XM, Zhuang Q, Yang MH, Wang W, et al
    [Value of four-dimensional echocardiography combined with speckle tracking technique on the assessment of right heart function and prognosis in patients with pulmonary arterial hypertension].
    Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46:965-971.
    Abstract    
    
    Abstract available
    
    

58. CHANG H, Chang CY, Lee HJ, Chou CY, et al
    Magnolol ameliorates pneumonectomy and monocrotaline-induced pulmonary arterial hypertension in rats through inhibition of angiotensin II and endothelin-1 expression.
    Phytomedicine. 2018;51:205-213.
    Abstract    
    
    Abstract available
    
    

59. GUERRA G, Perrotta F, Testa G
    Circulating Endothelial Progenitor Cells Biology and Regenerative Medicine in Pulmonary Vascular Diseases.
    Curr Pharm Biotechnol. 2018;19:700-707.
    Abstract    
    
    Abstract available
    
    

60. RADEGRAN G
    [Riskstratification in pulmonary arterial hypertension - renders better treatment and prognosis at highly specialised centers].
    Lakartidningen. 2018;115.
    Abstract    
    
    Abstract available
    
    

61. SHARMA A, Pandey NN, Kumar S
    Pulmonary capillary haemangiomatosis causing pulmonary arterial hypertension: a clinician's conundrum.
    BMJ Case Rep. 2018;2018.
    Abstract    
    
    
    
    

62. DUBIN RF
    Application of echocardiographic data in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 May 16. doi: 10.1097/MNH.0000000000000419.
    Abstract    
    
    Abstract available
    
    

63. TANAKA T, Eckardt KU
    HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
    Semin Nephrol. 2018;38:267-276.
    Abstract    
    
    Abstract available
    
    

64. NOEL ZR
    Safety concerns regarding selexipag in pulmonary arterial hypertension.
    Am J Health Syst Pharm. 2018;75:420.
    Abstract    
    
    
    
    

65. HAYASAKA I, Cho K, Akimoto T, Ikeda M, et al
    Genetic basis for childhood interstitial lung disease among Japanese infants and children.
    Pediatr Res. 2018;83:477-483.
    Abstract    
    
    Abstract available
    
    

66. PUDASAINI B, Yang GL, Yang C, Guo J, et al
    Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients.
    BMC Cardiovasc Disord. 2018;18:56.
    Abstract    
    
    Abstract available
    
    

67. MATSUMURA I
    [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
    Rinsho Ketsueki. 2018;59:13-26.
    Abstract    
    
    Abstract available
    
    

68. ZHAO QH, Wu WH, Gong SG, Jiang R, et al
    [Clinical and imaging features of pulmonary veno-occlusive disease and pulmonary capillary hemangioma].
    Zhonghua Jie He He Hu Xi Za Zhi. 2018;41:41-46.
    Abstract    
    
    Abstract available
    
    

69. RODRIGUEZ-ALMENDROS N, Toapanta-Yanchapaxi LN, Aguirre Valadez J, Espinola Zavaleta N, et al
    [Portopulmonary hypertension: Updated review].
    Arch Cardiol Mex. 2018;88:25-38.
    Abstract    
    
    Abstract available
    
    

70. GONZALEZ-CANDIA A, Veliz M, Carrasco-Pozo C, Castillo RL, et al
    Antenatal melatonin modulates an enhanced antioxidant/pro-oxidant ratio in pulmonary hypertensive newborn sheep.
    Redox Biol. 2019;22:101128.
    Abstract    
    
    Abstract available
    
    

71. VADASZ Z, Balbir Gurman A, Meroni P, Farge D, et al
    Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study.
    Rheumatology (Oxford). 2019 Feb 15. pii: 5321177.
    Abstract    
    
    Abstract available
    
    

72. KARLSSON J, Wallin M, Hallback M, Lonnqvist PA, et al
    Capnodynamic determination of cardiac output in hypoxia-induced pulmonary hypertension in pigs.
    Br J Anaesth. 2019;122:335-341.
    Abstract    
    
    Abstract available
    
    

73. ZHA LH, Zhou J, Li TZ, Luo H, et al
    NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
    J Cell Physiol. 2019 Feb 14. doi: 10.1002/jcp.28255.
    Abstract    
    
    Abstract available
    
    

74. SANCHEZ MEJIA AA, Rodgers NJ
    Evaluation and Monitoring of Pulmonary Hypertension in Neonates With Congenital Diaphragmatic Hernia.
    Curr Treat Options Cardiovasc Med. 2019;21:11.
    Abstract    
    
    Abstract available
    
    

75. BHATTACHARYA S, Sen S, Levy PT, Rios DR, et al
    Comprehensive Evaluation of Right Heart Performance and Pulmonary Hemodynamics in Neonatal Pulmonary Hypertension : Evaluation of cardiopulmonary performance in neonatal pulmonary hypertension.
    Curr Treat Options Cardiovasc Med. 2019;21:10.
    Abstract    
    
    Abstract available
    
    

76. YOUNG A, Vummidi D, Visovatti S, Homer K, et al
    Prevalence, Treatment and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
    Arthritis Rheumatol. 2019 Feb 14. doi: 10.1002/art.40862.
    Abstract    
    
    Abstract available
    
    

77. VELDHOEN RA, Chan W, Mahaffey R, D'Arsigny CL, et al
    Traumatic Pulmonary Hypertension Secondary to Arteriovenous Fistula and Remote Gunshot Wound.
    Can J Cardiol. 2019;35:229.
    Abstract    
    
    Abstract available
    
    

78. KIMURA M, Kohno T, Kawakami T, Kataoka M, et al
    Shortening Hospital Stay Is Feasible and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty.
    Can J Cardiol. 2019;35:193-198.
    Abstract    
    
    Abstract available
    
    

79. OPITZ I, Kirschner MB
    Molecular Research in Chronic Thromboembolic Pulmonary Hypertension.
    Int J Mol Sci. 2019;20.
    Abstract    
    
    Abstract available
    
    

80. BRYCE YC, Perez-Johnston R, Bryce EB, Homayoon B, et al
    Pathophysiology of right ventricular failure in acute pulmonary embolism and chronic thromboembolic pulmonary hypertension: a pictorial essay for the interventional radiologist.
    Insights Imaging. 2019;10:18.
    Abstract    
    
    Abstract available
    
    

81. CYGULSKA K, Wejner-Mik P, Plewka M, Figiel L, et al
    Roxadustat - another drug that causes pulmonary hypertension? - first human report.
    Pol Arch Intern Med. 2019 Feb 13. doi: 10.20452/pamw.4445.
    Abstract    
    
    
    
    

82. CANTONI S, Cavalli S, Pastore F, Accetta A, et al
    Pharmacological characterization of a highly selective Rho-kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension.
    Eur J Pharmacol. 2019 Feb 9. pii: S0014-2999(19)30102.
    Abstract    
    
    Abstract available
    
    

83. YU X, Zhao X, Zhang J, Li Y, et al
    Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension.
    Eur J Pharmacol. 2019 Feb 9. pii: S0014-2999(19)30095.
    Abstract    
    
    Abstract available
    
    

84. NGUYEN QT, Jalloul Nsaibia M, Sirois MG, Calderone A, et al
    PBI-4050 Reduces Pulmonary Hypertension, Lung fibrosis and Right Ventricular Dysfunction in Heart Failure.
    Cardiovasc Res. 2019 Feb 7. pii: 5308607. doi: 10.1093.
    Abstract    
    
    Abstract available
    
    

85. LAMMI MR, Saketkoo LA, Okpechi SC, Ghonim MA, et al
    Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers.
    Respirology. 2019 Feb 12. doi: 10.1111/resp.13500.
    Abstract    
    
    Abstract available
    
    

86. CIRULIS MM, Ryan JJ, Archer S
    EXPRESS: Pathophysiology, incidence, management and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Pulm Circ. 2019 Feb 12:2045894019834890. doi: 10.1177/2045894019834890.
    Abstract    
    
    
    
    

87. DAS B, Jadotte MM, Mills J, Chan KC, et al
    Digital Subtraction Pulmonary Angiography in Children with Pulmonary Hypertension due to Bronchopulmonary Dysplasia.
    Med Sci (Basel). 2019;7.
    Abstract    
    
    Abstract available
    
    

88. XIONG PY, Tian L, Dunham-Snary KJ, Chen KH, et al
    Biventricular Increases in Mitochondrial Fission Mediator (MiD51) and Proglycolytic Pyruvate Kinase (PKM2) Isoform in Experimental Group 2 Pulmonary Hypertension-Novel Mitochondrial Abnormalities.
    Front Cardiovasc Med. 2019;5:195.
    Abstract    
    
    Abstract available
    
    

89. NEIDENBACH R, Niwa K, Oto O, Oechslin E, et al
    Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part II: infective endocarditis, pulmonary hypertension, pulmonary arterial hypertension and aortopathy.
    Cardiovasc Diagn Ther. 2018;8:716-724.
    Abstract    
    
    Abstract available
    
    

90. ALVAREZ-TRONCOSO J, Robles-Marhuenda A
    Pulmonary hypertension in lupus.
    Lupus. 2019 Feb 10:961203319827653. doi: 10.1177/0961203319827653.
    Abstract    
    
    
    
    

91. JONE PN, Ivy DD
    Comprehensive Noninvasive Evaluation of Right Ventricle-Pulmonary Circulation Axis in Pediatric Patients with Pulmonary Hypertension.
    Curr Treat Options Cardiovasc Med. 2019;21:6.
    Abstract    
    
    Abstract available
    
    

92. FRANK BS, Runciman M, Manning WA, Ivy DD, et al
    Pulmonary Hypertension Secondary to Scurvy in a Developmentally Typical Child.
    J Pediatr. 2019 Feb 6. pii: S0022-3476(19)30020.
    Abstract    
    
    
    
    

93. HEKIMSOY V
    An overlooked aspect in the assessment of systolic pulmonary arterial pressure in female patients with hyperthyroidism.
    Anatol J Cardiol. 2019;21:54-55.
    Abstract    
    
    
    
    

94. GIESZER B, Radeczky P, Ghimessy A, Farkas A, et al
    [The start of the Hungarian lung transplantation program and the first results].
    Orv Hetil. 2018;159:1859-1868.
    Abstract    
    
    Abstract available
    
    

95. YANG PP, Yang YH, Kuang TG, Yang MF, et al
    [Pulmonary cavities with Takayasu arteritis: report of 3 cases and literature review].
    Zhonghua Jie He He Hu Xi Za Zhi. 2018;41:787-792.
    Abstract    
    
    Abstract available
    
    

96. RIOU M, Jutant EM, Mignard X, Canuet M, et al
    [Liver diseases and pulmonary vascular disorders].
    Rev Med Interne. 2018;39:925-934.
    Abstract    
    
    Abstract available
    
    

97. BALMERT NJ, Prahlow JA
    Childhood Idiopathic Pulmonary Arterial Hypertension Complicated by Esophageal Intubation: A Case Report.
    Am J Forensic Med Pathol. 2019;40:94-98.
    Abstract    
    
    Abstract available
    
    

98. LI C, Liu PP, Tang DD, Song R, et al
    Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.
    Pulm Pharmacol Ther. 2018;50:111-122.
    Abstract    
    
    Abstract available
    
    

99. LIN H, Wang M, Yu Y, Qin Z, et al
    Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis.
    Pulm Pharmacol Ther. 2018;50:1-10.
    Abstract    
    
    Abstract available
    
    

100. GUO DC, Li YD, Yang YH, Zhu WW, et al
     Influence of impaired right ventricular contractile reserve on exercise capacity in patients with precapillary pulmonary hypertension: A study with exercise stress echocardiography.
     Echocardiography. 2019 Feb 22. doi: 10.1111/echo.14283.
     Abstract    
     
     Abstract available
     
     

101. ODEVOGLU P, Demir R, Okumus G, Kucukoglu MS, et al
     Validity and reliability of the Turkish version of the EmPHasis-10 questionnaire in patients with pulmonary hypertension.
     J Eval Clin Pract. 2019 Feb 22. doi: 10.1111/jep.13115.
     Abstract    
     
     Abstract available
     
     

102. AGUIRRE-CAMACHO A
     Behavioral and Psychologic Symptoms in Patients With Pulmonary Hypertension: A Response to Dogan et al.
     Psychosomatics. 2019 Jan 23. pii: S0033-3182(19)30019.
     Abstract    
     
     
     
     

103. PERROTTA F, Nigro E, Mollica M, Costigliola A, et al
     Pulmonary Hypertension and Obesity: Focus on Adiponectin.
     Int J Mol Sci. 2019;20.
     Abstract    
     
     Abstract available
     
     

104. KAWAKUBO M, Yamasaki Y, Kamitani T, Sagiyama K, et al
     Clinical usefulness of right ventricular 3D area strain in the assessment of treatment effects of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: comparison with 2D feature-tracking MRI.
     Eur Radiol. 2019 Feb 21. pii: 10.1007/s00330-019-6008.
     Abstract    
     
     Abstract available
     
     

105. XI SB, Wang SS, Qian MY, Xie YM, et al
     Predictors of operability in children with severe pulmonary hypertension associated with congenital heart disease.
     Chin Med J (Engl). 2019 Feb 15. doi: 10.1097/CM9.0000000000000145.
     Abstract    
     
     Abstract available
     
     

106. ZHANG JJ, Chen JH, Zhao MP, Wu YL, et al
     [The role of endoplasmic reticulum stress in pulmonary hypertension in rat induced by chronic hypoxia and hypercapnia].
     Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2018;34:327-333.
     Abstract    
     
     Abstract available
     
     

107. ZHANG CC, Zhang JJ, Chen JH, Wu YL, et al
     [The effect of Yiqi Wenyang Huoxue Huatan Fang on hypoxia-hypercarbia induced pulmonary hypertension and its mechanism].
     Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2018;34:408-413.
     Abstract    
     
     Abstract available
     
     

108. GIRSBERGER M, Thenganatt J, Chan CT
     Correction of pulmonary hypertension with intensive hemodialysis: A case report.
     Hemodial Int. 2019 Feb 20. doi: 10.1111/hdi.12691.
     Abstract    
     
     Abstract available
     
     

109. AGRAWAL V, Byrd BF 3rd, Brittain EL
     Echocardiographic evaluation of diastolic function in the setting of pulmonary hypertension.
     Pulm Circ. 2019;9:2045894019826043.
     Abstract    
     
     Abstract available
     
     

110. LI X, Wu BX, Li H, Wang MM, et al
     [Effect of calcium-sensitive receptors on endothelial nitric oxide synthase and nitric oxide in neonatal mice with persistent pulmonary hypertension].
     Zhongguo Dang Dai Er Ke Za Zhi. 2019;21:189-194.
     Abstract    
     
     Abstract available
     
     

111. MONTALVA L, Antounians L, Zani A
     Pulmonary hypertension secondary to congenital diaphragmatic hernia: factors and pathways involved in pulmonary vascular remodeling.
     Pediatr Res. 2019 Feb 19. pii: 10.1038/s41390-019-0345.
     Abstract    
     
     Abstract available
     
     

112. TAJIMA H, Kasai H, Tanabe N, Sugiura T, et al
     EXPRESS: Clinical characteristics and prognosis in patients with chronic thromboembolic pulmonary hypertension and a concomitant psychiatric disorder.
     Pulm Circ. 2019 Feb 19:2045894019836420. doi: 10.1177/2045894019836420.
     Abstract    
     
     
     
     

113. KRAMER T, Dumitrescu D, Gerhardt F, Orlova K, et al
     Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
     Int J Cardiol. 2019 Jan 4. pii: S0167-5273(18)35398.
     Abstract    
     
     Abstract available
     
     

114. IKEDA N, Kubota S, Okazaki T, Iijima R, et al
     The predictors of complications in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
     Catheter Cardiovasc Interv. 2019 Feb 17. doi: 10.1002/ccd.28133.
     Abstract    
     
     Abstract available
     
     

115. YAMASAKI G, Okano M, Nakayama K, Jimbo N, et al
     Acute Pulmonary Hypertension Crisis after Adalimumab Reduction in Rheumatoid Vasculitis.
     Intern Med. 2019;58:593-601.
     Abstract    
     
     Abstract available
     
     

116. KURODA K, Akagi S, Nakamura K, Sarashina T, et al
     Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
     Heart Lung Circ. 2019 Feb 7. pii: S1443-9506(19)30048.
     Abstract    
     
     Abstract available
     
     

117. WOODCOCK CC, Chan SY
     The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
     J Cardiovasc Pharmacol Ther. 2019 Feb 17:1074248419829172.
     Abstract    
     
     Abstract available
     
     

118. DOBSON L, Stutzman SE, Hicks AD, Olson DM, et al
     Sleep hygiene in patients with chronic respiratory disease.
     Nursing. 2019;49:64-69.
     Abstract    
     
     Abstract available
     
     

119. STEINHORN RH
     Trends in PDA treatment: is less really more?
     J Pediatr. 2018;203:2.
     Abstract    
     
     
     
     

120. LI D, Sun Y, Kong X, Luan C, et al
     Association between a Single Nucleotide Polymorphism in the 3'-UTR of ARHGEF18 and the Risk of Nonidiopathic Pulmonary Arterial Hypertension in Chinese Population.
     Dis Markers. 2018;2018:2461845.
     Abstract    
     
     Abstract available
     
     

121. LI X, Qian YQ, Liu N, Mu R, et al
     Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study.
     Clin Rheumatol. 2018;37:3051-3056.
     Abstract    
     
     Abstract available
     
     

122. LEVY PT, Patel MD, Singh GK
     Reply.
     J Pediatr. 2018;202:336-337.
     Abstract    
     
     
     
     

123. LIU Z, Wang J, Lai J, Wang Q, et al
     Is it possible to apply the treat-to-target strategy in primary Sjogren's syndrome-associated pulmonary arterial hypertension?
     Clin Rheumatol. 2018;37:2989-2998.
     Abstract    
     
     Abstract available
     
     

124. FRAIDENBURG DR, Machado RF
     A Review of Transcriptome Analysis in Pulmonary Vascular Diseases.
     Methods Mol Biol. 2018;1783:259-277.
     Abstract    
     
     Abstract available
     
     

125. SOUMAGNE T, Dalphin JC
     Current and emerging techniques for the diagnosis of hypersensitivity pneumonitis.
     Expert Rev Respir Med. 2018;12:493-507.
     Abstract    
     
     Abstract available
     
     

126. ZHANG H, Liu Y, Yan L, Du W, et al
     Bone morphogenetic protein-7 inhibits endothelial-mesenchymal transition in pulmonary artery endothelial cell under hypoxia.
     J Cell Physiol. 2018;233:4077-4090.
     Abstract    
     
     Abstract available
     
     

127. ZWIJNENBURG RD, Baggen VJM, Witsenburg M, Boersma E, et al
     Risk Factors for Pulmonary Hypertension in Adults After Atrial Septal Defect Closure.
     Am J Cardiol. 2019 Jan 24. pii: S0002-9149(19)30103.
     Abstract    
     
     Abstract available
     
     

128. SMILOWITZ NR, Armanious A, Bangalore S, Ramakrishna H, et al
     Cardiovascular Outcomes of Patients With Pulmonary Hypertension Undergoing Noncardiac Surgery.
     Am J Cardiol. 2019 Feb 8. pii: S0002-9149(19)30171.
     Abstract    
     
     Abstract available
     
     

129. SU J, Logan CC, Hughes AD, Parker KH, et al
     Impact of chronic hypoxia on proximal pulmonary artery wave propagation and mechanical properties in rats.
     Am J Physiol Heart Circ Physiol. 2018;314:H1264-H1278.
     Abstract    
     
     Abstract available
     
     

130. BARMAN SA, Li X, Haigh S, Kondrikov D, et al
     Galectin-3 is Expressed in Vascular Smooth Muscle Cells and Promotes Pulmonary Hypertension through changes in Proliferation, Apoptosis and Fibrosis.
     Am J Physiol Lung Cell Mol Physiol. 2019 Feb 6. doi: 10.1152/ajplung.00186.2018.
     Abstract    
     
     Abstract available
     
     

131. DODSON MW, Allen-Brady K, Brown LM, Elliott CG, et al
     Chronic Thromboembolic Pulmonary Hypertension Cases Cluster in Families.
     Chest. 2019;155:384-390.
     Abstract    
     
     Abstract available
     
     

132. YU Q, Tai YY, Tang Y, Zhao J, et al
     BOLA3 Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.
     Circulation. 2019 Feb 14. doi: 10.1161/CIRCULATIONAHA.118.035889.
     Abstract    
     
     Abstract available
     
     

133. KOESTENBERGER M, Avian A, Meinel K, Sallmon H, et al
     Author Response to LTE CLC-18-0673 entitled "Diagnostic and Prognostic Value of Echocardiography in Pulmonary Arterial Hypertension".
     Clin Cardiol. 2018 Aug 1. doi: 10.1002/clc.23038.
     Abstract    
     
     Abstract available
     
     

134. DANDEL M, Hetzer R
     Diagnostic and Prognostic Value of Echocardiography in Pulmonary Arterial Hypertension.
     Clin Cardiol. 2018 Aug 1. doi: 10.1002/clc.23036.
     Abstract    
     
     Abstract available
     
     

135. TOTARO P, Pelenghi S
     Patient-prosthesis mismatch after mitral valve replacement: complex enigma with more than one solution.
     Eur J Cardiothorac Surg. 2018 Apr 19. pii: 4978191. doi: 10.1093.
     Abstract    
     
     
     
     

136. HOEPER MM, Boucly A, Sitbon O
     Age, risk and outcomes in idiopathic pulmonary arterial hypertension.
     Eur Respir J. 2018;51.
     Abstract    
     
     
     
     

137. BADLAM JB, Austin ED
     Beyond oestrogens: towards a broader evaluation of the hormone profile in pulmonary arterial hypertension.
     Eur Respir J. 2018;51.
     Abstract    
     
     
     
     

138. GUIGNABERT C, de Man F, Lombes M
     ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad.
     Eur Respir J. 2018;51.
     Abstract    
     
     
     
     

139. SKORO-SAJER N, Gerges C, Balint OH, Kohalmi D, et al
     Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension.
     Heart. 2018;104:1195-1199.
     Abstract    
     
     Abstract available
     
     

140. RAM E, Sternik L, Klempfner R, Eldar M, et al
     Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery.
     J Cardiothorac Vasc Anesth. 2018 Dec 25. pii: S1053-0770(18)31180.
     Abstract    
     
     Abstract available
     
     

141. HUBBARD R, Miller R, Tumin D, Tobias JD, et al
     Transplant outcomes for idiopathic pulmonary hypertension in children.
     J Heart Lung Transplant. 2019 Feb 5. pii: S1053-2498(19)31344.
     Abstract    
     
     
     
     

142. CHAOUAT A, Cherifi A, Sitbon O, Girerd N, et al
     [Evaluation of cardiac MRI in the follow up assessment of patients with pulmonary arterial hypertension].
     Rev Mal Respir. 2018;35:749-758.
     Abstract    
     
     Abstract available
     
     

143. WANG L, Liu J, Wang W, Qi X, et al
     Targeting IL-17 attenuates hypoxia-induced pulmonary hypertension through downregulation of beta-catenin.
     Thorax. 2019 Feb 18. pii: thoraxjnl-2018-211846.
     Abstract    
     
     Abstract available
     
     

144. NAITO A, Hiwasa T, Tanabe N, Sanada TJ, et al
     Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension.
     PLoS One. 2019;14:e0211377.
     Abstract    
     
     Abstract available
     
     

145. KURDYUKOV S, Eccles CA, Desai AA, Gonzalez-Garay M, et al
     New cases of Glucose-6-Phosphate Dehydrogenase deficiency in Pulmonary Arterial Hypertension.
     PLoS One. 2018;13:e0203493.
     Abstract    
     
     Abstract available
     
     

146. NAKAMURA K, Sakaguchi M, Matsubara H, Akagi S, et al
     Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension.
     PLoS One. 2018;13:e0203046.
     Abstract    
     
     Abstract available